Ahmad S. Halwani
( out of 64 reviews )

Ahmad S. Halwani, MD

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Research North

2D, Hematology
Salt Lake City
801-585-2626

  • Dr. Ahmad Halwani is an Associate Professor of Medicine in the Division of Hematology and Hematologic Malignancies in the Department of Internal Medicine at the University of Utah. He is also a staff physician and health services researcher at the Informatics, Decision Enhancement, & Analytics Sciences (IDEAS) Center of Innovation at the George E Whalen Veterans Administration (VA) Medical Center in Salt Lake City, and serves as a cancer data subject matter expert and health information technology implementation expert for the VA National Oncology Program. He is a University of Utah VP Clinical and Translational scholar (2016), NCI Cancer Clinical Investigator Team Leadership awardee (2018), and serves on the National Comprehensive Cancer Network panels on cutaneous and T-cell lymphoma.

    His work focuses on leveraging EHR data to build data products, analytics, and user interfaces that support provider workflows, improving care quality, effectiveness and safety, as well as facilitating novel tele-oncology models of care. Previous work includes leading the data and analytic efforts allowing VA National Oncology Program to provide congress with a report on access to germ line genetic testing in Veterans with breast cancer; reporting on implementation of the Veterans Symptom Assessment System; developing, evaluating and maintaining health information technology tools and systems supporting the missions of the VA Breast and Gynecological Cancer System of Excellence, VA Cancer Care Navigation and Tracking, VA Clinical Trial Navigation Center, medication management of oral anticancer treatment, and others. Analytic products have focused on leveraging deep learning and generative large language models in supporting provider workflows.

    To schedule an appointment: New Patients: 801-585-6906 Returning Patients: 801-585-2626 or schedule through MyChart.

    For questions regarding our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist (801) 587-4630.

    Specialties

    Board Certification

    American Board of Internal Medicine (Sub: Medical Oncology)
    Educational Commission for Foreign Medical Graduates

    Patient Rating

    4.8 /5
    ( out of 64 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    February 10, 2025
    HUNTSMAN CANCER CENTER

    Dr. Halwani is very personable and caring. He makes time to listen and talk with a person.

    December 22, 2024
    HUNTSMAN CANCER CENTER

    Highly recommend Dr. Halwani who is experienced, takes his profession seriously, yet has a good sense of humor.

    November 05, 2024
    HUNTSMAN CANCER CENTER

    He is always so friendly and positive. Always makes me feel relaxed and important.

    October 30, 2024
    HUNTSMAN CANCER CENTER

    Dr. Halwani is the best doctor I have ever had! He is so kind and caring, I'm grateful he is my doctor.

    October 23, 2024
    HUNTSMAN CANCER CENTER

    Dr. Halwani has been the most excellent Doctor I would have no trouble recommending him to anyone

    October 06, 2024
    HUNTSMAN CANCER CENTER

    Dr. Halwani and his superior team is the gold standard of care. Thorough, insightful and compassionate. I am so grateful my health is in his care!

    September 29, 2024
    HUNTSMAN CANCER CENTER

    Dr Halwani is very caring and always makes sure I understand everything.

    September 29, 2024
    HUNTSMAN CANCER CENTER

    Dr. Halwani is wonderful. I'm grateful to ge in his care.

    June 30, 2024
    HUNTSMAN CANCER CENTER

    Dr. Halwani is a thoughtful, experienced and caring physician. My husband has been seeing him regularly from his initial non-Hopkins Lymphoma in 2011. Doctor listens carefully and engages one's confidence immediately. We highly recommend Dr. Halwani.

    See More Patient Comments

  • Dr. Ahmad Halwani is an Associate Professor of Medicine in the Division of Hematology and Hematologic Malignancies in the Department of Internal Medicine at the University of Utah. He is also a staff physician and health services researcher at the Informatics, Decision Enhancement, & Analytics Sciences (IDEAS) Center of Innovation at the George E Whalen Veterans Administration (VA) Medical Center in Salt Lake City, and serves as a cancer data subject matter expert and health information technology implementation expert for the VA National Oncology Program. He is a University of Utah VP Clinical and Translational scholar (2016), NCI Cancer Clinical Investigator Team Leadership awardee (2018), and serves on the National Comprehensive Cancer Network panels on cutaneous and T-cell lymphoma.

    His work focuses on leveraging EHR data to build data products, analytics, and user interfaces that support provider workflows, improving care quality, effectiveness and safety, as well as facilitating novel tele-oncology models of care. Previous work includes leading the data and analytic efforts allowing VA National Oncology Program to provide congress with a report on access to germ line genetic testing in Veterans with breast cancer; reporting on implementation of the Veterans Symptom Assessment System; developing, evaluating and maintaining health information technology tools and systems supporting the missions of the VA Breast and Gynecological Cancer System of Excellence, VA Cancer Care Navigation and Tracking, VA Clinical Trial Navigation Center, medication management of oral anticancer treatment, and others. Analytic products have focused on leveraging deep learning and generative large language models in supporting provider workflows.

    To schedule an appointment: New Patients: 801-585-6906 Returning Patients: 801-585-2626 or schedule through MyChart.

    For questions regarding our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist (801) 587-4630.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Associate Professor (Clinical)
    Academic Divisions Hematology & Hematologic Malignancies
    Board Certification
    American Board of Internal Medicine (Sub: Medical Oncology)
    Educational Commission for Foreign Medical Graduates

    Education history

    Fellowship Medical Oncology - University of Iowa Hospitals & Clinics Fellow
    Fellowship Allergy and Immunology - University of Iowa Hospitals & Clinics Fellow
    Residency Internal Medicine - University of Iowa Hospitals & Clinics Resident
    Professional Medical Medicine - American University of Beirut M.D.
    Undergraduate Biology with High Distinction - American University of Beirut B.S.

    Selected Publications

    Journal Article

    1. Fu YV, Ramachandran GK, Halwani A, McInnes BT, Xia F, Lybarger K, Yetisgen M, Uzuner (2024). CACER: Clinical concept Annotations for Cancer Events and Relations. J Am Med Inform Assoc, 31(11), 2583-2594. (Read full article)
    2. Shepherd-Banigan M, Zullig LL, Berkowitz TSZ, Cummin G, Goldstein KM, Kelley MJ, Chawla N, Weidenbacher HJ, Hazra A, Halwani AS, Patil V, Rasmussen KM, Pace R, Colonna S, Moss H (2024). Improving Cancer Care for Women Seeking Services in the Veterans Health Administration Through the Breast and Gynecological Oncology System of Excellence. Mil Med. (Read full article)
    3. Monreal I, Chappell H, Kiss R, Friedman DR, Akesson J, Sae-Hau M, Szumita L, Halwani A, Weiss ES (2024). Understanding the Barriers to Clinical Trial Referral and Enrollment Among Oncology Providers Within the Veterans Health Administration. Mil Med. (Read full article)
    4. Rasmussen KM, Patil V, Li C, Yong C, Appukkuttan S, Grossman JP, Jhaveri J, Halwani AS (2023). Survival Outcomes by Race and Ethnicity in Veterans With Nonmetastatic Castration-Resistant Prostate Cancer. JAMA Netw Open, 6(10), e2337272. (Read full article)
    5. Burningham Z, Jackson GL, Kelleher JL, Morris I, Stevens MB, Cohen J, Maloney G, Sauer BC, Halwani AS, Chen W, Vaughan CP (2023). Use of a Medication Safety Audit and Feedback Tool in the Emergency Department Is Affected by Prescribing Characteristics. Appl Clin Inform, 14(4), 684-692. (Read full article)
    6. Shah H, Jang H, Kim S, Halwani AS (2022). A comprehensive SEER registry analysis of elderly patients with classical Hodgkin lymphoma based on treatment era and race. Br J Haematol, 200(5), 579-586. (Read full article)
    7. Parsons MW, Wada DA, Halwani AS, Tao R, Gaffney DK (2022). Improved overall survival over time in advanced stage mycosis fungoides: a cross-sectional study. Leuk Lymphoma, 63(10), 2428-2435. (Read full article)
    8. Burningham Z, Lagha RR, Duford-Hutchinson B, Callaway-Lane C, Sauer BC, Halwani AS, Bell J, Huynh T, Douglas JR, Kramer BJ (2022). Developing the VA Geriatric Scholars Programs' Clinical Dashboards Using the PDSA Framework for Quality Improvement. Appl Clin Inform, 13(4), 961-970. (Read full article)
    9. Friedman DR, Halwani AS, Kelley MJ (2022). Reply to B.L. King-Kallimanis et al. JCO Clin Cancer Inform, 6, e2200075. (Read full article)
    10. Abbott J, Corean J, Laggis C, Halwani A, Toydemir R, Miles R, Florell S, Wada D (2022). Histological Transformation and Clonal Relationship of Subcutaneous Marginal Zone B-Cell Lymphoma and Diffuse Large B-Cell Lymphoma. Am J Dermatopathol, 44(6), 442-448. (Read full article)
    11. Passey D, Healy R, Qualls J, Hamilton CJ, Tilley E, Burningham Z, Sauer B, Halwani A (2022). Development and implementation of a pharmacist-led telehealth medication management program for veterans receiving oral antineoplastic therapies through the MISSION Act. Am J Health Syst Pharm, 79(11), 835-843. (Read full article)
    12. Halwani AS, Panizo C, Isufi I, Herrera AF, Okada CY, Cull EH, Kis B, Chaves JM, Bartlett NL, Ai W, de la Cruz-Merino L, Bryan LJ, Houot R, Linton K, Briones J, Chau I, von Keudell GR, Lu H, Yakovich A, Chen M, Meulen Jh T, Yurasov S, Hsu FJ, Flowers CR (2021). Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. Leuk Lymphoma, 63(4), 821-833. (Read full article)
    13. Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Brammer J, Clemens MW, Dogan A, Foss F, Ghione P, Goodman AM, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kallam A, Kim YH, Kumar K, Mehta-Shah N, Olsen EA, Rajguru SA, Rozati S, Said J, Shaver A, Shea L, Shinohara MM, Sokol L, Torres-Cabala C, Wilcox R, Wu P, Zain J, Dwyer M, Sundar H (2022). T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 20(3), 285-308. (Read full article)
    14. Friedman DR, Patil V, Li C, Rassmussen KM, Burningham Z, Hamilton-Hill S, Kelley MJ, Halwani AS (2022). Integration of Patient-Reported Outcome Measures in the Electronic Health Record: The Veterans Affairs Experience. JCO Clin Cancer Inform, 6, e2100086. (Read full article)
    15. Chien HC, Morreall D, Patil V, Rasmussen KM, Yong C, Li C, Passey DG, Burningham Z, Sauer BC, Halwani AS (2021). Treatment Patterns and Outcomes in a Nationwide Cohort of Older and Younger Veterans with Waldenström Macroglobulinemia, 2006-2019. Cancers (Basel), 13(7). (Read full article)
    16. Li C, Patil V, Rasmussen KM, Yong C, Chien HC, Morreall D, Humpherys J, Sauer BC, Burningham Z, Halwani AS (2021). Predicting Survival in Veterans with Follicular Lymphoma Using Structured Electronic Health Record Information and Machine Learning. Int J Environ Res Public Health, 18(5). (Read full article)
    17. Chien HC, Morreall D, Patil V, Rasmussen KM, Li C, Yong CM, Burningham Z, Masaquel A, Halloran M, De Long-Sieg E, Schulz M, Sauer BC, Halwani AS (2020). Real-world practice patterns and outcomes in Veterans with relapsed/refractory diffuse large B-cell lymphoma. Future Oncol, 17(4), 411-422. (Read full article)
    18. Passey DG, Healy R, Qualls J, Halwani A, Sauer BC (2020). Pharmacist-led collaborative medication management programs for oral antineoplastic therapies: A systematic literature review. J Am Pharm Assoc (2003), 61(3), e7-e18. (Read full article)
    19. Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Clemens MW, Dogan A, Goodman AM, Goyal G, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kim YH, Mehta-Shah N, Olsen EA, Pro B, Rajguru SA, Rozati S, Said J, Shaver A, Shustov A, Sokol L, Torka P, Torres-Cabala C, Wilcox R, William BM, Zain J, Dwyer MA, Sundar H (2020). NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021. J Natl Compr Canc Netw, 18(11), 1460-1467. (Read full article)
    20. Halwani AS, Rasmussen KM, Patil V, Morreall D, Li C, Yong C, Burningham Z, Dawson K, Masaquel A, Henderson K, DeLong-Sieg E, Sauer BC (2020). Maintenance rituximab in Veterans with follicular lymphoma. Cancer Med, 9(20), 7537-7547. (Read full article)
    21. Richter Lagha R, Burningham Z, Sauer BC, Leng J, Peters C, Huynh T, Patel S, Halwani AS, Kramer BJ (2020). Usability Testing a Potentially Inappropriate Medication Dashboard: A Core Component of the Dashboard Development Process. Appl Clin Inform, 11(4), 528-534. (Read full article)
    22. Mehta-Shah N, Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Clemens MW, Dogan A, Fisher K, Goodman AM, Goyal G, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Lunning MA, Mehta A, Olsen EA, Pro B, Rajguru SA, Shanbhag S, Shaver A, Shustov A, Sokol L, Torka P, Torres-Cabala C, Wilcox R, William BM, Zain J, Dwyer MA, Sundar H, Kim YH (2020). NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020. J Natl Compr Canc Netw, 18(5), 522-536. (Read full article)
    23. Rasmussen KM, Patil V, Burningham Z, Yong C, Sauer BC, Halwani AS (2020). Atrial Fibrillation and Bleeding in Patients With Chronic Lymphocytic Leukemia Treated with Ibrutinib in the Veterans Health Administration. Fed Pract, 37(Suppl 2), S44-S49. (Read full article)
    24. Halwani AS, Rasmussen KM, Patil V, Li CC, Yong CM, Burningham Z, Gupta S, Narayanan S, Lin SW, Carroll S, Mhatre SK, Graff JN, Dreicer R, Sauer BC (2019). Real-world practice patterns in veterans with metastatic castration-resistant prostate cancer. Urol Oncol, 38(1), 1.e1-1.e10. (Read full article)
    25. Walsh JA, Pei S, Penmetsa GK, Sauer BC, Patil V, Walker JH, Clewell J, Douglas KM, Clegg DO, Cannon GW, Halwani A (2019). Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis. J Manag Care Spec Pharm, 25(11), 1218-1228. (Read full article)
    26. Burningham Z, Chen W, Sauer BC, Richter Lagha R, Hansen J, Huynh T, Patel S, Leng J, Halwani A, Kramer BJ (2019). VA Geriatric Scholars Program's impact on prescribing potentially inappropriate medications. Am J Manag Care, 25(9), 425-430. (Read full article)
    27. Peters CB, Hansen JL, Halwani A, Cho ME, Leng J, Huynh T, Burningham Z, Caloyeras J, Matsuda T, Sauer BC (2019). Validation of Algorithms Used to Identify Red Blood Cell Transfusion Related Admissions in Veteran Patients with End Stage Renal Disease. EGEMS (Wash DC), 7(1), 23. (Read full article)
    28. Elkeeb D, Hopkins Z, Miles RR, Halwani A, Wada D (2019). Ominous cutaneous presentation of acute myeloid leukemia without peripheral blood involvement upon initial presentation and relapse: case report and literature review. Eur J Dermatol, 28(6), 809-817. (Read full article)
    29. Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M, MAVORIC Investigators (2018). Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol, 19(9), 1192-1204. (Read full article)
    30. Burningham Z, Leng J, Peters CB, Huynh T, Halwani A, Rupper R, Hicken B, Sauer BC (2018). Predicting Psychiatric Hospitalizations among Elderly Veterans with a History of Mental Health Disease. EGEMS (Wash DC), 6(1), 7. (Read full article)
    31. Horwitz SM, Ansell SM, Ai WZ, Barnes J, Barta SK, Choi M, Clemens MW, Dogan A, Greer JP, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Kim YH, Lunning MA, Mehta A, Mehta-Shah N, Oki Y, Olsen EA, Pro B, Rajguru SA, Shanbhag S, Shustov A, Sokol L, Torka P, Wilcox R, William B, Zain J, Dwyer MA, Sundar H (2018). NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018. J Natl Compr Canc Netw, 16(2), 123-135. (Read full article)
    32. Merryman RW, Kim HT, Zinzani PL, Carlo-Stella C, Ansell SM, Perales MA, Avigdor A, Halwani AS, Houot R, Marchand T, Dhedin N, Lescaut W, Thiebaut-Bertrand A, Franois S, Stamatoullas-Bastard A, Rohrlich PS, Labussire Wallet H, Castagna L, Santoro A, Bachanova V, Bresler SC, Srivastava A, Kim H, Pesek E, Chammas M, Reynolds C, Ho VT, Antin JH, Ritz J, Soiffer RJ, Armand P (2017). Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood, 129(10), 1380-1388. (Read full article)
    33. Vrontikis A, Carey J, Gilreath JA, Halwani A, Stephens DM, Sweetenham JW (2016). Proposed Algorithm for Managing Ibrutinib-Related Atrial Fibrillation. Oncology (Williston Park), 30(11), 970-4, 980-1, C3. (Read full article)
    34. Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ, Lebovic D, Dhodapkar M, Avigan D, Chapuy B, Ligon AH, Freeman GJ, Rodig SJ, Cattry D, Zhu L, Grosso JF, Bradley Garelik MB, Shipp MA, Borrello I, Timmerman J (2016). Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. J Clin Oncol, 34(23), 2698-704. (Read full article)
    35. McPherson JP, Vrontikis A, Sedillo C, Halwani AS, Gilreath JA (2016). Pralatrexate Monitoring Using a Commercially Available Methotrexate Assay to Avoid Potential Drug Interactions. Pharmacotherapy, 36(2), e8-e11. (Read full article)
    36. Colonna S, Halwani A, Ying J, Buys S, Sweeney C (2015). Women with breast cancer in the Veterans Health Administration: demographics, breast cancer characteristics, and trends. Med Care, 53(4 Suppl 1), S149-55. (Read full article)
    37. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P (2015). PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med, 372(4), 311-9. (Read full article)
    38. Nelson SD, Lu CC, Teng CC, Leng J, Cannon GW, He T, Zeng Q, Halwani A, Sauer B (2015). The use of natural language processing of infusion notes to identify outpatient infusions. Pharmacoepidemiol Drug Saf, 24(1), 86-92. (Read full article)
    39. Ontiveros EP, Halwani A, Stunz LL, Kamberos N, Olivier AK, Janz S, Bishop GA (2014). A new model of LMP1-MYC interaction in B cell lymphoma. Leuk Lymphoma, 55(12), 2917-23. (Read full article)
    40. Han SS, Tompkins VS, Son DJ, Kamberos NL, Stunz LL, Halwani A, Bishop GA, Janz S (2013). Piperlongumine inhibits LMP1/MYC-dependent mouse B-lymphoma cells. Biochem Biophys Res Commun, 436(4), 660-5. (Read full article)
    41. Halwani AS, Link BK (2011). Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma. Expert Rev Anticancer Ther, 11(3), 443-55. (Read full article)
    42. Racila E, Link BK, Weng WK, Witzig TE, Ansell S, Maurer MJ, Huang J, Dahle C, Halwani A, Levy R, Weiner GJ (2008). A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res, 14(20), 6697-703. (Read full article)

    Review

    1. Post AR, Burningham Z, Halwani AS (2022). Electronic Health Record Data in Cancer Learning Health Systems: Challenges and Opportunities. [Review]. JCO Clin Cancer Inform, 6, e2100158. (Read full article)

    Letter

    1. Chien HC, Morreall D, Patil V, Rasmussen KM, Yong CM, Li CY, Passey DG, Burningham Z, Sauer BC, Halwani AS (2021). Real-world treatment patterns and outcomes in a national study of veterans with Waldenström macroglobulinemia, 2006-2019. [Letter to the editor]. Am J Hematol, 96(6), E184-E187. (Read full article)
    2. Laggis CW, Lamb A, Secrest AM, Ufkes N, Halwani AS, Tao R, Gaffney D, Miles RR, Florell SR, Wada D (2020). Favourable outcomes in folliculotropic mycosis fungoides after multimodality treatment in a single institution. [Letter to the editor]. J Eur Acad Dermatol Venereol, 35(1), e42-e45. (Read full article)

    Abstract

    1. Kim YH, Bagot M, Eradat HA, Carson KR, Greer JP, Kim EJ, Kuzel T, Hughey LC, Poligone B, Lansigan F, Zinzani PL, Grandinetti LM, Procu P, Shustov AR, Korman NJ, Halwani A, Sokol L, Duvic M (01012014). Phase 3 study of anti-CCR4 monoclonal antibody mogamulizumab vs vorinostat in relapsed or refractory cutaneous t-cell lymphoma (CTCL). [Abstract]. J Clinical Oncology American Society of Clinicial Oncology annual meeting.
    2. Lesokhin A, Gutierrez M, Halwani A, Ansell SM, Armand P, Borrello I, Segota ZE, Cohen AD, Talpaz M, Cattry D, Turner T, Mezes M, Hartman C, Gupta A, Kim SY, Wigginton JM, Timmerman JM (01012014). A Phase 1 Dose Escalation Study Evaluating the Effects of Nivolumab (anti-PD-1; BMS-936558) in Patients with Select Relapsed or Refractory Hematologic Malignancies. [Abstract]. J Clinical Oncology American Society of Clinicial Oncology annual meeting.
    3. Halwani A, Stunz S, Hu L, Janz S, Bishop G (2010). A new mouse lymphoma model, the iMycEµ-LMP1 transgenic mouse, suggests collaboration of LMP1 and Myc in lymphomagenesis. Poster Presentation; University of Iowa Carver College of Medicine, College of Pharmacy, College of Public Health, Institute for Clinical and Translational Science and VA Health System Research Week. [Abstract].
    4. Halwani A, Ballas Z (2009). Progression of Selective IgM Deficiency to Common Variable Immunodeficiency. Journal of Allergy and Clinical Immunology. Poster Presentation, AAAAI annual meeting [Abstract]. 123(2, Supplement 1), S89.
    5. Halwani A (2008). Eczematous Rash, Elevated IgE & Recurrent Infections. Presented at the Clinical Immunology Society Primary Immunodeficiency Summer School. [Abstract].
    6. Halwani A, Ballas Z (2008). Delayed Recovery of T Cell Response Post Cyclosporin Therapy. Journal of Allergy and Clinical Immunology. Poster Presentation, AAAAI annual meeting. [Abstract]. 121(2, Supplement 1), S87.
    7. Halwani A, Gingrich R (2005). An Unusual Tonsillitis. American College of Physicians, Iowa Chapter, Associates Clinical Vignette Competition. [Abstract].

    Research Lab